longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Upstream Bio

UPB

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Weekly Recap | Zai Lab -2.8%, most brokers rate it buy

    Weekly Review·Sep 26 at 07:23 AM
    - Zai Lab shares fell 2.8% to close at 24.98 USD this week, underperforming the S&P 500 index by 4.01 percentage points amid shrinking trading volume and no major catalysts. - Among 12 covering institutions, 9 rated the stock as a buy and 2 as overweight, resulting in a strong buy consensus with an average target price of 33.14 USD. - Next week's focus will center on US macroeconomic data impacting the biotechnology sector's risk appetite, while Zai Lab has no major events or earnings reports scheduled.
    ZLAB+2.84%
  • Weekly Recap | Sarepta Therap -7.16%, consensus target above spot

    Weekly Review·Sep 26 at 07:08 AM
    SRPT+0.70%SRPU0.00%
  • Weekly Recap | Novavax +5.14%, consensus target above spot

    Weekly Review·Sep 26 at 06:55 AM
    NVAX+1.60%
  • Weekly Recap | Legend Biotech +8.52%, most brokers rate it buy

    Weekly Review·Sep 26 at 06:37 AM
    LEGN-2.56%
  • Weekly Recap | IOVA.US +7.32%, most brokers rate it buy

    Weekly Review·Sep 26 at 06:33 AM
    IOVA-0.09%
  • Weekly Recap | GENB.US -11.61%, consensus target above spot

    Weekly Review·Sep 26 at 06:23 AM
    GENB-1.58%
  • Weekly Recap | Cypherpunk Tech +14.44%, a sharp V-shaped recovery

    Weekly Review·Sep 26 at 06:13 AM
    CYPH-19.66%
  • Weekly Recap | CRISPR Therap -4.12%, most brokers rate it buy

    Weekly Review·Sep 26 at 06:12 AM
    CRSP-0.26%
  • Weekly Recap | Upstream Bio -6.81%, consensus target above spot

    Weekly Review·Sep 19 at 07:06 AM
    UPB-1.12%
  • Weekly Recap | Upstream Bio -4.66%, consensus target above spot

    Weekly Review·Sep 12 at 06:58 AM
    UPB-1.12%
  • The Nasdaq Biotechnology Index rose over 2.6%, outperforming the broader US stock market. Among constituents, Sarepta Therapeutics surged 34.98%, Summit Therapeutics Plc. rose 15.53%, Enliven Therapeutics increased 14.06%, Upstream Bio gained 12.07%, Taysha Gene climbed 10.90%, Gossamer Bio advanced 10.61%, and Oruka Therapeutics was up 9.80%. Conversely, Aardvark Therapeutics fell 6.10%, ADMA Biologics dropped 15.23%, Anavex Life Sciences declined 34.61%, and Maze Therapeutics fell 35.24%

    Wallstreetcn·Mar 25 at 08:50 PM
    XBI+1.02%TSHA+6.85%